https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2790396?guestAccessKey=85cae594-b783-41ca-84f5-34ac5ab6ef39&utm_source=silverchair&utm_campaign=jama_network&utm_content=healthpolicy_highlights&cmp=1&utm_medium=email

https://www.medscape.com/viewarticle/970974

	Tom Insel, MD ⁦‪@thomasinselmd‬⁩ The crisis of care is not just lack of access but lack of engagement. The majority of people with #mentalillness are not in treatment. And the 40% who are in treatment receive low-quality care, so only 1/3 of those in care will experience the full benefit. We must do better. pic.twitter.com/b8MkXuoqG0 3/31/22, 12:01 PM

	STAT ⁦‪@statnews‬⁩ The pharmaceutical industry is still struggling to tackle Alzheimer’s disease. Now, health tech companies are now trying to take a crack at it. buff.ly/3uK6mIa 3/31/22, 7:00 AM

The Biggs article includes the Daily Record Scale which is use in treatment studies.

All sources comment the mechanism of RX is specific to the SSRI as opposed to antidepressants and cite a) immediate clinical effect in PMDD b) lack of effect from non-SRI antidepressants.

Occasional use of the SSRI (ie symptoms onset ) as opposed to daily use is simply to minimize side effect.

The issue of increasing the dose temporarily for patients already on SSRI I did not see addressed.

JT

Joseph (Joe) E. Thornton, M.D., DFAPA
Adjunct Clinical Associate Professor, Psychiatry
University of Florida College of Medicine
joethornton@ufl.edu

CONFIDENTIALITY NOTIFICATION: Please be advised! This e-mail message, including any attachments, has been created explicitly for the sole use of the intended recipient(s) and may contain confidential and privileged information. The materials in this message are private and may contain Protected Healthcare Information or other information of a sensitive nature. If you are not the intended recipient, be advised that any unauthorized use, disclosure, copying or the taking of any action in reliance on the contents of this information is strictly prohibited. If you have received this email in error, please immediately notify the sender via telephone or return mail. Any unauthorized review, use, disclosure, or distribution of such information is prohibited and will be upheld under the discretion of Federal and State law. If you have received this e-mail message in error and are not an intended recipient, please contact the sender via reply e-mail or phone and destroy all copies of the original message. Pursuant to ‘ FS 766.101, FS 395.0193, FS 395.0197, FS 766.1016 and other Statutes, this document is privileged and confidential. It is not subject to discovery. Please do NOT copy or release.

Biggs WS and Demuth 2011 Review of RX PMDD AmFamPhy.pdf

Carlini S et al 2021 EBm rx of PMDD.pdf

Premenstrual Dysphoric Disorder – StatPearls – NCBI Bookshelf.pdf

	Vandenbroucke lab ⁦‪@Vdb_lab‬⁩ Alzheimer’s disease has an alarming increasing prevalence. We urgently need to improve our understanding behind the pathogenesis. In ⁦‪@FrontImmunol‬⁩ we now give a comprehensive overview on how systemic and intestinal inflammatory processes may affect brain pathology. pic.twitter.com/V8FN8ibW9l 3/24/22, 7:03 AM

	JAMA Psychiatry ⁦‪@JAMAPsych‬⁩ This systematic review and meta-analysis explored the outcomes and moderators of psychological interventions delivered by nonspecialists for #depression in low- and middle-income countries. ja.ma/355nlMp #globalhealth #mentalhealth 3/24/22, 6:00 PM

https://jamanetwork.com/journals/jama/fullarticle/2790276

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790171?utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamanetworkopen&utm_content=wklyforyou&utm_term=032322